Pituitary Macroadenoma Manifesting As Acromegaly: A Case Report

Dian Primadia Putri, Brama Ihsan Sazli

Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Medan, North Sumatera, Indonesia

Abstract. Background: Acromegaly is an uncommon clinical disorder driven by high serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Over 99% of patients with acromegaly harbor a GH emitting pituitary adenoma. Pituitary tumors represent about 15% of essential intracranial neoplasms. Case presentation: A 38 years old woman, was referred to the H. Adam Malik central public hospital on December 15th, 2020, with chief complaints of enlarged fingers and toes. The patient complained that the patient's fingers and toes were getting bigger in the past 2 years. The brain MRI was performed showed intrasella spherical intensity lesions measuring ± 2.3x1.5x2 cm with the impression of macroadenoma. The patient later diagnosed with acromegaly due to pituitary macroadenoma. Therefore the patient was treated with administration of sandostatin injection, novorapid 6-6-6 IU SC, then 0-0-12 IU SC, 3x1 salt capsules. The patient is also consulted to the neurosurgery department for surgical management plans and a consulted to the Ophthalmology Department. Conclusion: We report an instance of acromegaly suspected because of pituitary macroadenoma in a patient with unmistakable clinical highlights, with comprehensive management.

Keyword: Acromegaly, Macroadenoma Pituitary

Abstrak: Latar belakang: Akromegali adalah kelainan klinis yang jarang akibat peninggian growth hormone (GH) serum dan insulin-like growth factor 1 (IGF-1). Lebih dari 99% pasien dengan akromegali memiliki adenoma hipofisis yang menstimulasi GH. Tumor hipofisis mewakili sekitar 15% dari neoplasma intrakranial esensial. Presentasi kasus: Seorang wanita berusia 38 tahun, dirujuk ke Rumah Sakit Umum Pusat H. Adam Malik pada tanggal 15 Desember 2020, dengan keluhan utama jari tangan dan kaki membesar. Pasien mengeluh jari tangan dan kaki pasien semakin membesar dalam 2 tahun terakhir. MRI otak yang dilakukan menunjukkan lesi intensitas sferis intrasella berukuran ± 2,3x1,5x2 cm dengan kesan makroadenoma. Pasien kemudian didiagnosis dengan akromegali akibat makroadenoma hipofisis. Oleh karena itu pasien dirawat dengan pemberian injeksi sandostatin, novorapid 6-6-6 IUSC, kemudian 0-0-12 IUSC, kapsul garam 3x1. Pasien juga akan dikonsultasikan ke departemen bedah saraf untuk rencana manajemen bedah dan dikonsultasikan ke departemen oftalmologi. Kesimpulan: Dilaporkan seorang pasien akromegali yang dicurigai karena makroadenoma hipofisis pada pasien dengan gambaran klinis yang jelas, dan dengan manajemen yang komprehensif.

Kata kunci: Akromegali, Makroadenoma Hipofisis

Received 24 January 2021 | Revised 27 February 2021 | Accepted 28 February 2021

*Corresponding author at: Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Medan, North Sumatera, Indonesia
E-mail address: drdianprimadiaputri@gmail.com

Copyright © 2021 Published by Talenta Publisher, ISSN: 2686-0872 e-ISSN: 2686-0856
DOI: https://doi.org/10.32734/jetromi.v3i1.5482
Journal Homepage: https://jetromi.usu.ac.id
Attribution-NonCommercial-ShareAlike 4.0 International
1 Introduction

Acromegaly is an uncommon clinical disorder driven by high serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The frequency of acromegaly is 3–4 cases for each million populace, and its commonness is assessed to go from 38 to 69 cases for every million [1]. Since a portion of the clinical profiles related to acromegaly are vague and the indications of the issue are treacherous, a few patients go undiscovered for quite a while after the beginning of starting signs and side effects [2]. Over 99% of patients with acromegaly harbor a GH emitting pituitary adenoma. Normal term from manifestations beginning to analysis is regularly 4–10 years. Pituitary tumors represent about 15% of essential intracranial neoplasm. Given the basic area of the organ, extending tumors cause compressive side effects. At the point when tumors emerge in pituitary somatotroph cells, unusual emission of GH prompts the particular highlights of acromegaly. Practical pituitary adenomas are the most widely recognized reason for acromegaly, and the beginning of the infection is naturally steady, prompting a generous postponement in determination and treatment [3,4]. Early finding and brief treatment of this problem are indispensable as it conveys up to 72% expansion on the whole reason mortality when contrasted with everyone [5]. Allegedly, internists analyze 40% of acromegaly cases while the rest of analyzed by experts seen for specific side effects, for example, an ophthalmologist for visual aggravations [6]. We report an instance of acromegaly suspected because of pituitary macroadenoma in a patient with unmistakable clinical highlights.

2 Case Illustration

A 38 years old woman, was referred to the H. Adam Malik Hospital on December 15th, 2020, with chief complaints of enlarged fingers and toes (Fig. 1). The patient complained that the patient's fingers and toes were getting bigger in the past 2 years and the patient felt that it disturbed the patient's daily life so that the patient felt insecure about doing activities. Patients also realized that the face shape is getting more oval for about 2 years. The patient also noticed a widening of the forehead and thickening of the patient's nose and lips which arose with enlargement of the patient's fingers and toes. The patient also complained about the growing number of fine hairs on the patient's face, abdomen, and thighs, which the patient experienced for approximately 1 year and increased in these 6 months. The patient also complained of frequent sweating even though the patient was not doing strenuous activities or the weather was cold.
Blurred eyes were also complained of by patients who were found in patients since 3 months ago and have become more severe since 1 month, blurred vision, especially in the outer field of view of the left and right eyes, the patient has difficulty reading small letters in newspapers or books and there is no change if the patient changes the distance between the newspapers or books that the patient reads. The patient has gone to an ophthalmologist and this complaint does not improve with the use of glasses.

Headaches have also been experienced by the patient for 6 months and have worsened for this month, the headache is felt like throbbing and is felt evenly throughout the patient's head, sometimes it is also felt in certain areas of the patient's head, the patient's headaches are experienced and come on and off, then the headache is felt increasingly often and is felt continuously. Pain is felt reduced if she consumed anti-pain medication and then come back if you don't take pain medication, pain is felt so that sometimes it makes it difficult for the patient to do activities.

The patient complained of getting smaller breasts for about 1 year. The history of the milk out of the patient's breast was denied by the patient. Menstrual disorders were also experienced by patients in the form of prolonged menstrual periods around 10-14 days and irregular menstruation. In 2016 the patient was diagnosed with a pituitary tumor and an operation was performed through the nose at an outside hospital but in the past 2 years, the patient has felt complaints reappearing. The patient denied a history of high blood pressure and diabetes. The patient had a history of consuming Cripsa 2.5 mg twice a day.

From the examination, it was found that the patient body weight is 65 kg and height is 155 cm with a BMI of 27.1 Kg/m2 categorized as type 1 obesity. The vital sign examination was performed with a regular heart rate of 98 x/minit, blood pressure of 130/80 mmHg, the temperature of 36.7°C, and respiratory rate of 20x/minute. Physical examination showed prominent results as in facial appearances, with noticeable bigger nose and lips. A laboratory examination was performed on December 24th, 2020 consist of a complete blood count. Hb of 15.3 gr/dL, Ht of 44 gr/dL, leukocytes of 5.130/mm3 and platelets of 207.000/mm3, testosterone level with 0.52 nmol/L, fasting blood glucose level of 391 mg/dL, postprandial blood glucose level of 448 mg/dL and HbA1C 13.55. The brain MRI was performed on December 23th 2020, showed intrasellar spherical intensity lesions measuring ±2,3x1,5x2 cm, lesions resulting in compression of the optic chiasma (Fig. 2). The patient was later diagnosed with acromegaly due to pituitary macroadenoma. Therefore the patient was treated with administration of Sandostatin injection, Novo rapid 6-6-6 IU SC, then 0-0-12 IU SC, 3x1 salt capsules. The patient is also consulted to the Neurosurgery Department for surgical management plans and a consulted to the Ophthalmology Department.
3 Discussion

Acromegaly is an uncommon issue with clinical signs that are essentially credited to the foundational impact of supported hypersecretion of GH. Entanglements related to this problem incorporate cardiovascular brokenness, respiratory trade-off, malignancies, metabolic confusions, skeletal anomalies, rheumatologic arthropathies, and neuropathies [5]. A few reports show a twofold to triple-expansion in mortality when contrasted and everybody, with cardiovascular occasions representing most of the mortality [6]. Other eminent reasons for death incorporate respiratory confusions and malignancies [7]. The increment in grimness and mortality related to acromegaly might be part of the way because of the guileful and reformist nature of the infection, which regularly prompts postponed analysis or potentially treatment [8]. Hence, it is basic that clinicians from all claims to fame keep a high file of doubt on patients giving explicit side effects who have trademark dysmorphic highlights of acromegaly.

GH-emitting pituitary adenomas are the most well-known reason for acromegaly and as ongoing proof proposes, such tumors have a wide clinicopathologic variety [8]. This intertumoral heterogeneity clarifies why not all patients build up a quickly reformist aggregate and gives an understanding into the significant normal symptomatic deferral of eight years that is accounted for in numerous populace contemplates. Deferral in conclusion additionally likely clarifies why around 75% of somatotroph adenomas are identified as macroadenomas (adenoma > 10 mm) at the hour of analysis [9,10].

Current therapy alternatives incorporate transsphenoidal medical procedure, radiotherapy, or clinical treatment with dopamine agonists, somatostatin analogs, or GH receptors adversaries. Albeit skeletal and articular changes are perpetual, up to 70% of patients experience the goal of other foundational indications and metabolic difficulties [11].

Medical procedure, explicitly transsphenoidal adenectomy, seems, by all accounts, to be the pillar restorative methodology for most patients [4, 12]. Following finding and establishment of suitable treatment, it is additionally basic that a thorough workup of all organ frameworks engaged with this problem be sought after. The GH levels <2.5 ng/ml, youthful age, a more limited span of infection, and nonattendance of hypertension are indicators of longer endurance [7]. Untreated acromegaly is related to a huge dismalness and a decreased future. Cardiovascular illness is the main source of death [9].

4 Conclusion

We report an instance of acromegaly suspected because of pituitary macroadenoma in a patient with unmistakable clinical highlights, with comprehensive management.
REFERENCES

[1] Melmed S, Kleinberg DL. Anterior pituitary. Williams Textbook of Endocrinology. 10th ed. Philadelphia: WB Saunders company. p. 177-281. 2003

[2] Daly AF, Petrossians P, Beckers A. An overview of the epidemiology and genetics of acromegaly. J Endocrinol Invest. Vol, 28 (11 Suppl International): p.67–9. 2005

[3] Fernandez A, Karavitaki N, Wass JA: Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. vol, 72:p, 377-82. 2010 10.1111/j.1365-2265.2009.03667.x

[4] Akirov A, Asa SL, Amer L, Shimon I, Ezzat S: The clinicopathological spectrum of acromegaly. J Clin Med vol, 8:p, 1962. 2019 10.3390/jcm8111962

[5] Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab, vol, 93:p, 61–7. 2008

[6] Melmed S. Medical progress: Acromegaly. N Engl J Med, p. 355-8. 2006

[7] Nganga HK, Lubanga RP: Pituitary macroadenoma presenting with pituitary apoplexy, acromegaly and secondary diabetes mellitus - a case report. Pan Afr Med J., vol, 15:p, 39. 2013 10.11604/pamj.2013.15.39.2054

[8] Roerink SH, van Lindert EJ, van de Ven AC: Spontaneous remission of acromegaly and Cushing's disease following pituitary apoplexy: two case reports. Neth J Med, vol, 73:p, 242-6. 2015

[9] Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N: Epidemiology of acromegaly: review of population studies. Pituitary, vol, 20:p, 4-9. 2017 10.1007/s11102-016-0754-x

[10] Gadelha MR, Kasuki L, Lim DST, Fleseriu M: Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev, 40:268-332. 2019 10.1210/er.2018-00115

[11] Fraser LA, Lee D, Cooper P, Van Uum S: Remission of acromegaly after pituitary apoplexy: case report and review of literature. Endocr Pract., 15:725-31. 2009. 10.4158/ep09126.Crr

[12] Donangelo I, Melmed S. Treatment of acromegaly: future. Endocrine. 28:123–8. 2005